本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
UPL achieves the highest score globally in the agrochemicals sector and fourth highest in the chemicals industry in the Dow Jones Sustainability Index (DJSI) UPL is the only agrochemical company included in the DJSI World Index for the second consecutive year. LONDON, Dec. 20, 2024 /PRNewswire/ -- UPL Ltd. (NSE: UPL) (BSE: 512070) (LSE: UPLL), a global provider of sustainable agricultural solutions, has been ranked as the top agrochemicals company in the 2024 Dow Jones Sustainability Indices (DJSI) for the second year running, and achieved the fourth highest score globally in the chemicals industry. This marks the second consecutive year that UPL has been included in both the DJSI World and Emerging Markets Indices, recognizing the company's continued sector-leading sustainability performance. UPL's recognition by DJSI is based on the company's outstanding performance in achieving the highest scores in the agrochemical sector in the S&P Global 2024 Corporate Sustainability Assessment. The DJSI is a globally renowned benchmark for evaluating companies' Environment, Social, and Governance (ESG) performance. The DJSI World Index highlights the top 10% of leading global companies in each industry, reflecting their commitment to promoting sustainable development. In addition, the DJSI Emerging Markets Index honours the top 10% of the largest 800 companies in emerging markets, selected for their outstanding ESG practices. Jai Shroff, Chairman and Group CEO of UPL Group, said: "At UPL, we believe that agriculture lies at the heart of global sustainability efforts, and we are immensely proud to lead our sector in the DJSI for the second consecutive year. This recognition reaffirms our commitment to Reimagining Sustainability by demonstrating how agriculture can be a force for good - empowering farmers, enhancing food security, fostering sustainable development, and creating a brighter future for all." UPL's excellent sustainability rating places the company among the top global performers. This acknowledgement is a testament to UPL's commitment to leading sustainable practices across its global operations, aligning with the best-in-class benchmarks for investors who prioritize long-term shareholder value. NOTES TO EDITORS: About UPL Group UPL Ltd. (NSE: UPL, BSE: 512070, LSE GDR: UPLL) is a global provider of sustainable agricultural products and solutions that cover the entire agrifood value chain. With annual revenue exceeding $5bn, the company is one of the largest agriculture companies worldwide, serving growers in more than 130 countries. UPL Group consists of four pure-play platforms that include UPL Corporation Ltd. (UPL Corp); UPL Sustainable Agri Solutions Ltd. (SAS); Advanta Enterprises Ltd.; and Superform Chemistries Ltd. (FKA UPL Speciality Chemicals Ltd.). Together, these platforms are dedicated to Reimagining Sustainability and driving progress in our food system through our innovative OpenAg® approach. To learn more about UPL, please visit upl-ltd.com and follow us on LinkedIn, X, and Facebook. UPL Corporation Ltd. (UPL Corp) is a leading global crop protection and biological solutions company defining the future through sustainable agriculture and a grower-first mindset. With a robust portfolio of holistic solutions, UPL Corp aims to create shared growth and prosperity for farming communities, agriculture, and our planet. As the largest of UPL Group's pureplay platforms, UPL Corp contributes to around $4bn in annual revenue and is a leader in fostering collaboration through OpenAg® to develop advanced technologies for crop health and productivity.
One of the largest IGA deployments in Japan, ensuring governance and scalability for identity and rights management for 250 000 employees within the NTT Group PARIS, Dec. 10, 2024 /PRNewswire/ -- Eviden, the Atos Group business leading in digital, cloud, big data, and security today announced that NTT Group has selected its Identity Governance and Administration (IGA) solution to ensure governance and scalability for the identity and rights management of all of its approximately 250,000 employees in Japan. This implementation is one of the world's largest IGA projects and will strengthen NTT Group's cybersecurity while ensuring governance of identity and rights management for all its employees. NTT Comware, who had been considering an identity and rights management infrastructure to be used across all the companies of the NTT Group in Japan, began evaluating Evidian IGA's innovative identity and rights management model, performance, and scalability in 2020. After a successful proof of concept and extended evaluation, NTT Comware decided to adopt and deploy Evidian IGA, determining that it would enable stable operation of the NTT Group's large user base. David Leporini, Director of IAM Cybersecurity Products & General Manager of Evidian, Eviden, Atos Group, said, "This challenging large-scale IAM deployment into NTT's complex IT infrastructure was successfully addressed by our IGA solution and sets a new standard for IAM projects globally". Ken Komazawa, Vice President of Platform Services Department, Network & Cloud Division, NTT Comware: "After researching and evaluating several competing products, we chose Evidian IGA to support our back-office operations for our 250,000 employees across 115 group companies. Through trial and error, we've achieved a flexible identity and rights management model and fast processing speeds that can handle millions of provisioning tasks within hours. Evidian IGA is also essential for ID management associated with the large-scale personnel changes of approximately 50,000 employees that occur periodically within the NTT Group." Evidian IAM's strong position in Japan and across the Asia-Pacific region, along with its identity as part of the Eviden brand, solidifies its role as a global leader in secure identity governance. With over 900 organizations and more than 5 million users globally, Evidian IAM continues to expand its presence beyond Europe, notably in Japan and the U.S. As part of its continued collaboration with NTT Comware, Evidian IAM's team will provide ongoing support and enhancements to ensure the security and scalability of NTT Group's identity and rights management system. About NTT COMWARE CORPORATION NTT Comware, with the power of technology including our software development capabilities, aims to envision a future that is beneficial to people and society, and contributes to realize a prosperous world of connected hearts. Based on the quality and reliability that has supported social infrastructure in Japan, NTT Comware will sophisticate networks and platforms for the next generation, trigger social and industrial structual change, drive business expansion of the DOCOMO Group, and promote Digital Transformation of the NTT Group. For details, see here. https://www.nttcom.co.jp/english/about/ For NTT Comware services using Evidian IAM, see here. https://sc.nttcom.co.jp/english/iam/ About Eviden[1] Eviden is a next-gen technology leader in data-driven, trusted and sustainable digital transformation with a strong portfolio of patented technologies. With worldwide leading positions in advanced computing, security, AI, cloud and digital platforms, it provides deep expertise for all industries in more than 47 countries. Bringing together 47,000 world-class talents, Eviden expands the possibilities of data and technology across the digital continuum, now and for generations to come. Eviden is an Atos Group company with an annual revenue of c. € 5 billion. About Atos Atos is a global leader in digital transformation with c. 92,000 employees and annual revenue of c. € 10 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris. The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space. Press contactZohra Dali zohra.dali.external@eviden.com +33 (0) 6 71 92 71 87 [1] Eviden business is operated through the following brands: AppCentrica, ATHEA, Cloudamize, Cloudreach, Cryptovision, DataSentics, Edifixio, Energy4U, Engage ESM, Evidian, Forensik, IDEAL GRP, In Fidem, Ipsotek, Maven Wave, Profit4SF, SEC Consult, Visual BI, Worldgrid, X-Perion. Eviden is a registered trademark. © Eviden SAS, 2024. Logo: https://mma.prnasia.com/media2/2576190/Eviden_Logo.jpg?p=medium600
TAIPEI, Dec. 4, 2024 /PRNewswire/ -- Advantech, a leading provider of edge computing solutions, has expanded its x86 series platforms with AMD EPYC™ and Ryzen™ series processors. Tailored for servers, motherboards, and networks, these platforms can be implemented across edge, security, and cloud applications. They offer superior computing power, fast data transfer, and energy efficiency, making them ideal for 5G edge cloud, AI, machine learning, and enhanced data security. Advantech utilizes AMD EPYC™ and Ryzen™ processors to power its advanced servers, server boards, industrial motherboards, and network appliances, driving innovation in edge cloud computing and network security. Advantech & AMD: Driving Industrial Innovation Advantech, in partnership with AMD, offers powerful computing capaiblities,and tailored scalable solutions. New to the 5th AMD EPYC™ series processors, featuring "Zen 5" and "Zen 5c" core architectures with up to 128 cores, provide the ultimate host CPU performance for GPU-accelerated AI solutions. The AMD EPYC™ 9004 & 8004 series processors offer up to 96 cores for robust sever-grade performance, high bandwidth with PCIe Gen 5 and DDR5 support, and a certified AMD Instinct™ MI210 GPU card for AI acceleration. The AMD Ryzen™ Embedded 7000 series processors integrat high-performance, extensive I/O scalability, low-TDP processing, and AMD Radeon™ graphics for advanced 4K resolution. While the Ryzen™ Embedded V3000 series ensures reliable 24/7 network performance with enhanced security through AMD Secure Processors and Memory Guard. Advantech's professional services, including extended product longevity, BIOS customization, and advanced thermal solutions, make these platforms ideal for demanding workloads and long-term industrial use with optimized support for Ubuntu, CentOS, and Windows. Advantech & AMD: Expanding Solutions Across Domains Advantech and AMD drives powerful and scalable solutions across various industries, including AI-enabled solutions, industrial automation, telecom, and network security. With professional hardware design, delivering extensive I/O capabilities, ruggedized systems, and custom design services for harsh environments. these offerings deliver ultra-low latency, high throughput, and energy efficiency. Furthermore, Advantech's global partnerships with Tier 1 chip and ISV leaders ensure seamless deployment and integration of cutting-edge technology worldwide. Outstanding Edge Cloud Computing Solutions Advantech's SKY series servers deliver cutting-edge technology for accelerated computing across AI, cloud, and edge applications. By combining AMD EPYC™ processors with robust memory and flexible storage configurations, this series is equipped to handle the evolving demands of data-centric industries. The SKY-602E3 GPU server is driven by AMD EPYC™ 8004 Series processor. It boasts a memory arrangement comprisised of 6 DDR5 ECC/RDIMM slots, and excels in graphic processing for AI applications thanks to offering 4 PCIe 5.0 x16 slots, delivering solid performance and high bandwidth for tasks heavy on data. With its high expansion capabilities, it provides additional versatility benefits by implementing 4 PCIe 5.0 x8 slots for more GPU, networking, and DPU installations. The SKY-721E3 and SKY-821E3 are both equipped with AMD EPYC™ 9004/9005 Series processors, showcasing up to 128 cores, 11 PCIe Gen5 slots, and OCP 3.0 compatibility for strong computing capabilities. The servers are designed for high-performance edge applications, integrating multiple accelerators to bring AI computing to the edge. With various storage options, SKY-721E3 including up to 12 bays for 3.5" drives or 24 bays for 2.5" hot-swap SATA/SAS/NVMe drives, this server is optimized for storage-intensive applications, such as cloud computing, database management, and AI simulation usage. High Flexibility and Integration for Industrial Automation Advantech's AIMB-723 is built to meet the rigorous demands of advanced industrial automation, powered by AMD Ryzen™ 7000 Series processors to provide exceptional performance with energy efficiency for industrial edge applications. It features high-speed I/O options including USB 3.2 Gen 2 (10 Gbps), dual 2.5 Gigabit Ethernet, M.2, and SATA, all enhancing connectivity and data handling. To support legacy requirements, it includes PCI expansion and RS-232 serial I/O interfaces. The AIMB-723 supports a 3 slot discrete GPU and three PCIe add-on cards, meeting the demands of AI-driven machine vision and Automated Optical Inspection (AOI). Secure and Connected Network Security Solutions Advantech provides advanced network security appliances. The FWA-6183 is designed for heavy workloads, featuring dual AMD EPYC™ 9004 processors with up to 192 cores, ensuring top-tier performance for data centers and AI applications. The FWA-6183 is also compatible with AMD EPYC™ 9005 processors, ensuring future-proof capabilities. Its scalability, with 8 NMC (Network Module Card) slots, ensures seamless future network integration, while redundant power and cooling systems provide uninterrupted service. The FWA-5082, a 1U gateway for SD-WAN and NFV, utilizes single AMD EPYC™ 8004 processors with up to 64 cores. It can expand different connections and capabilities through 4 network module cards and also offer reliable 24/7 operating service. The FWA-1081 targets SMBs, providing cost-effective firewall and UTM solutions powered by AMD Ryzen™ Embedded V3000 processors with up to 8 cores, PoE+ support, and optional LTE/5G modules, offering versatile connectivity and strong security performance. Why Advantech? Unmatched Performance with AMD EPYC™ and Ryzen™ ProcessorsAdvantech's x86 platforms leverage the latest AMD processors, ensuring exceptional computing power, fast data transfers, and high energy efficiency. Future-Proof Scalability and FlexibilityWith PCIe Gen5 support and DDR5 memory, Advantech provides seamless expansion and upgrade options. Designed for Diverse Industrial ApplicationsRuggedized Advantech designs and extensive I/O connectivity create opportunities to thrive in challenging industrial conditions and demanding workloads. Commitment to Long-Term ReliabilityWith extended product longevity and BIOS customization services, Advantech products are built for continuous operations and industrial durability. Global Partnerships and SupportStrong ecosystem and complete global services ensure Advantech solutions are equipped with the latest advancements, enabling businesses to stay at the forefront of industrial innovation. For more information, please contact sdn.nfv@advantech.com or visit AMD-based platform website.
MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography (PET) imaging of clear cell renal cell carcinoma (ccRCC). The patient was successfully dosed and imaged at Beijing Cancer Hospital in Beijing, China. ZIRCON-CP is a multi-centre Phase III registration trial in China intended to bridge to Telix's global Phase III ZIRCON trial, which met all co-primary and secondary endpoints, including showing 86% sensitivity and 87% specificity, and a mean positive-predictive value (PPV) of 93% for ccRCC[1]. The trial, which will enrol up to 82 patients, is being conducted in collaboration with the Company's strategic partner for the Greater China region, Grand Pharma, to demonstrate that the diagnostic utility of TLX250-CDx is equivalent in Chinese and Western populations. The clinical data from ZIRCON-CP is intended to support future marketing authorisation applications for this breakthrough technology. Greater China represents a major market opportunity for radiopharmaceuticals, including TLX250-CDx, driven by increasing cancer incidence rates and an investment in installation of PET/CT cameras. In China alone – 73,000 people are newly diagnosed with kidney cancer each year[2]. Dr David N. Cade, Chief Medical Officer at Telix said, "Dosing and imaging a first patient in the ZIRCON-CP trial is a significant milestone for Telix and our partner Grand Pharma. We would like to thank Professor Peng Du and his team, as well as the patients who will contribute to this important trial, helping to advance TLX250-CDx towards regulatory filings in Greater China, where there is currently critical unmet medical need." About TLX250-CDx TLX250-CDx (Zircaix®[3]) is an investigational PET agent that is under development to characterise indeterminate renal masses (IRMs) as ccRCC or non-ccRCC in a non-invasive manner. Telix's pivotal Phase III ZIRCON trial (Zirconium in Renal Cancer Oncology, ClinicalTrials.gov ID: NCT03849118) evaluating TLX250-CDx in 300 patients, of which 284 were evaluable, met all primary and secondary endpoints including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent readers. We believe this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing ccRCC. Confidence intervals exceeded expectations in all three readers, showing evidence of high accuracy and consistency of interpretation. As part of Telix's commitment to access to medicine, the Company continues to run an expanded access program (EAP) in the U.S.[4], named patient programs (NPPs) in Europe, and a special access scheme (SAS) in Australia to allow continued access to TLX250-CDx outside of a clinical trial to patients for whom there are no comparable or satisfactory alternate options. Telix's Policy on Offering Compassionate Use to Investigational Medicines can be downloaded at the following link. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[5], by the Australian Therapeutic Goods Administration (TGA)[6], and by Health Canada[7]. No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix®[3] names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. [1] Shuch et al. Lancet Oncol. 2024. Telix ASX disclosures 7 November 2022. [2] Globocan 2022. [3] Brand name subject to final regulatory approval. [4] ClinicalTrials.gov ID: NCT06090331. [5] Telix ASX disclosure 20 December 2021. [6] Telix ASX disclosure 2 November 2021. [7] Telix ASX disclosure 14 October 2022.
亞特蘭大2024年11月20日 /美通社/ -- 業界一流的伺服器設計暨製造商，神達控股股份有限公司(股票代號：3706)子公司神雲科技股份有限公司(MiTAC Computing Technology Corp.)，今日於美國亞特蘭大 SC24 展會自家攤位#2543展示了一系列全新伺服器。這些伺服器整合了最新的 AMD EPYC™ 9005 系列處理器、AMD Instinct™ MI325X 加速器、Intel® Xeon® 6處理器與專業級GPU，為 HPC 和 AI 工作負載提供卓越的優化效能。 神雲科技整合最新CPU與GPU技術，SC24展示AI/HPC伺服器新品 為 AI 驅動的資料中心工作負載提供領先效能與密度 搭載 AMD EPYC 9005 系列處理器，神雲科技新一代伺服器專為高效能 AI 運算工作負載進行優化設計，提升資料中心的效能與運算密度。在這次的 SC24 大會，神雲科技重點展示了兩款優秀的 AI/HPC 伺服器產品：首先是MiTAC G8825Z5，一款 8U雙路 AI 伺服器，支援最新 AMD Instinct MI325X 加速器，並可搭載最高 6TB 的 DDR5 6000 記憶體，提供 8 個熱插拔 NVMe U.2 托盤，非常適用於大規模 AI 與 HPC 基礎架構的建置需求。其次是MiTAC TYAN TN85-B8261，一款2U雙路GPU伺服器，專為HPC和深度學習應用設計，支援最多 4 張雙寬 GPU 卡、24 個 DDR5 RDIMM 插槽，並擁有 8 個熱插拔 NVMe U.2托盤。而在雲端伺服器方面，神雲科技展出MiTAC TYAN GC68C-B8056，這款1U單路伺服器能搭載 24 個 DDR5 DIMM 插槽與 12 個熱插拔NVMe U.2托盤，為雲端環境提供高效能與靈活的擴展性。此外，神雲科技還展出專為高 IOPS NVMe資料儲存設計的MiTAC TYAN TS70A-B8056 2U 單路伺服器，以及採用2U 4 節點架構設計的 MiTAC M2810Z5 單路伺服器，MiTAC M2810Z5 的每個節點最高可支援3,072GB的RDIMM DDR5 6000 記憶體與 4 個熱插拔 E1.S 硬碟，為高密度雲端伺服器的優異解決方案。 滿足AI與加速需求：可擴展效能提升投資效益並降低功耗 SC24大會上，神雲科技也展出基於Intel Xeon 6處理器，並具備優異性能和效率的次世代伺服器產品；首先是MiTAC R2520G6，這款2U雙路的通用型伺服器專為記憶體密集運算設計，支援高達8TB的DDR5記憶體、5個PCIe 5.0 x16插槽並提供 NVMe U.2和E1.s 靈活的儲存媒介選項。接著是MiTAC R2513G6，這台2U單路儲存伺服器支援24個3.5寸SATA硬碟和2個2.5寸NVMe硬碟，並提供 8 個 DDR5 記憶體插槽，同時內建 SAS RAID 卡實現高效可靠的資料儲存管理，適合高密度儲存應用場合。最後是MiTAC G4520G6，這是款專為平行式AI工作負載打造的4U雙路伺服器，支援多達8張雙插槽GPU卡、8TB DDR5 記憶體，並配備11個 PCIe 5.0 x16 插槽和 8 個熱插拔 U.2硬碟，是高性能運算和 AI 訓練的理想選擇。 此外，神雲科技還展示了英特爾 D50DNP 系列(Denali Pass)中的 D50DNP1MHCPLC 計算模組，這款1U半寬模組可支援兩顆功耗最高達 385W 的第5代/第4代Intel® Xeon® 可擴充處理器或Intel® Xeon® CPU Max 系列，採用直接液冷技術，具備16個DDR5 DIMM 記憶體插槽，最高可達5600 MT/s（搭配第 5 代Intel Xeon可擴展處理器）資料傳輸頻寬、2個半高半長 PCIe Gen 5 插槽以及多達 2 個 NVMe/SATA M.2 硬碟，為高密度計算應用提供了靈活與高效的解決方案。 除了前述介紹的產品，神雲科技在此次SC24大會也展示了其多元化的產品線，包括支援 AMD EPYC 9004/8004/4004 系列處理器、第5代/第4代Intel Xeon 可擴充處理器、Intel® Xeon® E-2400處理器以及專業級GPU的多款伺服器產品，提供符合現代用戶在性能與預算方面需要的各式解決方案。 關於神雲 神雲科技股份有限公司(MiTAC Computing Technology Corporation) 隸屬于神達控股股份有限公司(MiTAC Holdings Corp., TSE:3706)，擁有超過 30 年的伺服器設計與製造經驗，為雲端服務供應商、人工智慧/高性能運算，以及邊緣運算等不同的應用環境提供靈活的定制化供應模式。自 2023 年 7 月起，MiTAC開始承接英特爾資料中心解決方案事業群(DSG)伺服器產品之銷售與後續世代產品之規劃設計，為下一代資料中心設備提供先進的解決方案。MiTAC產品陣容涵蓋 TYAN 伺服器、ORAN 伺服器、高性能 AI 伺服器與資料中心產品，以豐富的產品範疇，提供給客戶全方位的企業級解決方案。 神雲原以 TYAN 品牌經營伺服器通路業務，於2023年7月起開始以 MiTAC 品牌經營 Intel DSG 伺服器產品之銷售。而為強化通路規劃、發揮品牌管理的綜效，並凝聚品牌形象，自2024年10月起，神雲整合 TYAN 與 MiTAC 兩個品牌，統一以 MiTAC 作為產品的品牌名稱。 神雲科技網站: http://www.mitaccomputing.com/ Intel, the Intel logo, and other marks are trademarks of Intel Corporation or its subsidiaries. AMD, the AMD Arrow logo, AMD Instinct, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
ATLANTA, Nov. 20, 2024 /PRNewswire/ -- MiTAC Computing Technology Corporation, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Holdings Corporation (TSE:3706), is unveiling its new server lineup at SC24, booth #2543, in Atlanta, Georgia. MiTAC Computing's servers integrate the latest AMD EPYC™ 9005 Series CPUs, AMD Instinct™ MI325X GPU accelerators, Intel® Xeon® 6 processors, and professional GPUs to deliver enhanced performance optimized for HPC and AI workloads. MiTAC Computing Unveils New AI/HPC-Optimized Servers with Advanced CPU and GPU Integration at SC24 Leading Performance and Density for AI-Driven Data Center Workloads MiTAC Computing's new servers, powered by AMD EPYC 9005 Series CPUs, are optimized for high-performance AI workloads. At SC24, MiTAC highlights two standout AI/HPC products: the 8U dual-socket MiTAC G8825Z5, featuring AMD Instinct MI325X GPU accelerators, up to 6TB of DDR5 6000 memory, and eight hot-swap U.2 drive trays, ideal for large-scale AI/HPC setups; and the 2U dual-socket MiTAC TYAN TN85-B8261, designed for HPC and deep learning applications with support for up to four dual-slot GPUs, twenty-four DDR5 RDIMM slots, and eight hot-swap NVMe U.2 drives. For mainstream cloud applications, MiTAC offers the 1U single-socket MiTAC TYAN GC68C-B8056, with twenty-four DDR5 DIMM slots and twelve tool-less 2.5-inch NVMe U.2 hot-swap bays. Also featured is the 2U single-socket MiTAC TYAN TS70A-B8056, designed for high-IOPS NVMe storage, and the 2U 4-node single-socket MiTAC M2810Z5, supporting up to 3,072 GB of DDR5 6000 RDIMM memory and four easy-swap E1.S drives per node. Meeting AI and Acceleration Needs: Scalable Performance to Enhance Investment and Save Power At SC24, MiTAC Computing presents its new Intel Xeon 6-based servers, offering trusted performance and exceptional efficiency. First is the 2U dual-socket general-purpose compute server, the MiTAC R2520G6, built for in-memory computing with up to 8TB of DDR5 memory, five PCIe 5.0 x16 slots, and flexible storage options for U.2 and E1.s SSDs. Next is the 2U single-socket storage server, MiTAC R2513G6, which supports twenty-four 3.5" SATA drives and two 2.5" NVMe drives, along with eight DDR5 memory slots with an integrated SAS RAID card for storage management. Finally, the 4U dual-socket MiTAC G4520G6 GPU server supports parallel AI workloads with up to eight GPUs, 8TB of DDR5 memory, eleven PCIe 5.0 x16 slots, and eight hot-swap U.2 drives. In addition, MiTAC Computing showcases one of the Intel® Server D50DNP Family (Denali Pass) SKUs, the D50DNP1MHCPLC, which supports up to 385W with two 5th/4th Gen Intel® Xeon® Scalable processors or Intel® Xeon® CPU Max Series. This 1U half-width compute module features direct liquid cooling, 8+8 DDR5 DIMMs up to 5600 MT/s (5th Gen), two low-profile PCIe Gen 5 slots, and up to two NVMe/SATA M.2 drives. Along with its previously showcased products, MiTAC Computing introduces a diverse server lineup at SC24, featuring AMD EPYC 9004/8004/4004 series processors, 5th/4th Gen Intel Xeon Scalable processors, Intel® Xeon® E-2400 processors and professional GPUs, providing solutions to meet the performance and budget needs of modern users. About MiTAC Computing Technology Corporation MiTAC Computing Technology Corporation, a subsidiary of MiTAC Holdings Corp. (TSE:3706), specializes in cloud, AI/HPC and edge computing solutions and has over 30 years of design and manufacturing expertise. With a strong focus on large-scale data centers, MiTAC offers flexible and customized solutions for various systems and applications. Our product lineup includes TYAN servers, ORAN servers, high-performance AI servers, and other data center products. Originally, MiTAC operated the server channel business under the TYAN brand and began selling Intel DSG server products under the MiTAC brand in July 2023. As of October 2024, we have integrated the TYAN and MiTAC brands to streamline our operations and enhance brand management. MiTAC now serves as the sole brand name for all our products. MiTAC Computing Technology Corporation website:http://www.mitaccomputing.com/ Intel, the Intel logo, and other marks are trademarks of Intel Corporation or its subsidiaries. AMD, the AMD Arrow logo, AMD Instinct, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
A12 藝術空間
SAS
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
